Results 231 to 240 of about 32,100 (296)

Venetoclax plus azacitidine, low‐dose cytarabine, aclarubicin, and G‐CSF (VA‐CAG regimen) for newly diagnosed young patients with acute myeloid leukemia: A prospective, multicenter, single‐arm Phase II clinical trial

HemaSphere, Volume 10, Issue 8, August 2026.
Abstract We conducted a prospective, multicenter, Phase II study to evaluate the safety and efficacy of venetoclax/azacitidine/low‐dose cytarabine/aclarubicin/granulocyte colony‐stimulating factor (G‐CSF) (VA‐CAG) in young patients with newly diagnosed acute myeloid leukemia (ND‐AML). The VA‐CAG regimen included venetoclax (100 mg/day, Days 1–2; 200 mg,
Xiaoping Li, Qiurong Zhang, Xiaoyan Li, Lin Liu, Yonglin Shen, Yu Li, Lihui Peng, Chaoyang Zhou, Chie Qiu, Zhongtao Yuan, Shiqian Hou, Youcheng Wang, Lihua Zhang, Jingqiong Li, Liang Zhao, Qiuyuan Tang, Zucong Chen, Jing Feng, Xuejuan Zhang, Guoxiu Bao, Kui Zhang, Renpeng Zhang, Shiqi Li, Yingnian Chen, Jianhua Rao, Yancheng Dong, Dingsong Zhang, Yueyuan Wang, Aifang Li, Xi Ye, Lei Lei, Jiao Chen, Sufen Xu, Yanling Jin, Chaoen Zheng, Yang Liang, Sanbin Wang   +36 more
wiley   +1 more source

Anthracyclines attenuate Nrf1-dependent proteolytic pathways and potentiate proteasome inhibitor cytotoxicity. [PDF]

Mol Biol Cell
Vangala JR, Ward MA, Albalawi B, Elshazly AM, Hosseini N, Shen S, Byers HA, Carter C, Liu J, Radhakrishnan SK.   +9 more
europepmc   +1 more source

The Therapeutic Potential of Stem Cell Therapy for Doxorubicin‐Induced Cardiotoxicity: A Narrative Review

Health Science Reports, Volume 9, Issue 8, August 2026.
ABSTRACT Background and Aims Doxorubicin (DOX) is a potent anthracycline chemotherapeutic agent whose clinical utility is significantly constrained by severe side effects, most notably DOX‐induced cardiotoxicity (DIC). Pathophysiological mechanisms of DIC include oxidative stress, mitochondrial dysfunction, programmed cell death, and inflammation ...
Ali Mirzaei, Pouria Rezaei, Reza Golchin Vafa, Saleheh Jahani, Reza Arefnezhad, Hossein Fatemian, Mohammad Hossein Nikoo, Amirhossein Sahebkar, Fatemeh Rezaei‐Tazangi   +8 more
wiley   +1 more source

Dexrazoxane Cardioprotection in pediatric ALL: a historical control cohort study. [PDF]

Cardiooncology
Liu L, Yang H, Zhou Y, Li N, Nie Q, Liu X, Yang C, Tian Y, Mao X, Li H, Guo Q, Tian X.   +11 more
europepmc   +1 more source

Morroniside Attenuates Doxorubicin‐Induced Cardiotoxicity by Activating the PI3K/AKT/Nrf2/HO‐1 Pathway to Inhibit Ferroptosis and Oxidative Stress

Journal of Biochemical and Molecular Toxicology, Volume 40, Issue 8, August 2026.
Mor activates the PI3K/AKT pathway to promote Nrf2 nuclear translocation and HO‐1 expression, enhancing antioxidants, curbing Fe2+‐induced ROS/lipid peroxidation, suppressing ferroptosis, and alleviating Dox‐induced cardiotoxicity. ABSTRACT Cardiotoxicity induced by doxorubicin (Dox) significantly contributes to increased mortality among cancer ...
Zhi‐Hui Lin, Xing‐Yu Lin, Wen‐Jie Lu, Meng‐Qi Wu, Dong‐Yan Song, Rui‐Dong Cheng   +5 more
wiley   +1 more source

Pharmacogenomic predictors of anthracycline-induced cardiotoxicity in breast cancer patients: a systematic review and meta-analysis. [PDF]

Cardiooncology
Bulusu VM, Shah B, Sawant S, Choudhary A, Das S, Jain S, Mallayasamy SR, Udupa KS, Arya N, Singh J, Rao M, Kanwar RK, Kumar A, Munisamy M.   +13 more
europepmc   +1 more source

Advances in the Treatment of Breast Cancer at Different Stages of Pregnancy. [PDF]

Onco Targets Ther
Lv J, Lin X.
europepmc   +1 more source

Reply: The CHECK HEART Score: A Practical Tool for Cardiotoxicity Risk Stratification. [PDF]

JACC Asia
Terui Y, Sugimura K.
europepmc   +1 more source

Cancer treatment-related cardiotoxicity, molecular mechanism, challenges, and research trends. [PDF]

Discov Oncol
Ling JY, Wen LM, Liu K, Yuan WQ, Zhong YM, Lai P, Liao YL.   +6 more
europepmc   +1 more source

Role of laser therapy in enhancing chemotherapy efficiency in breast cancer: low level laser therapy, photochemotherapy, and photodynamic therapy as promising treatments. [PDF]

Lasers Med Sci
Mohamed AE, Mohamed WR, Elhemely MA, Mohamed T.   +3 more
europepmc   +1 more source